We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Technique Identifies Initial Events in Tumor Development

By LabMedica International staff writers
Posted on 10 Oct 2011
A novel technique that enables scientists to measure and record tumor-inducing changes in DNA is providing new clues into the earliest events involved in the formation of leukemias, lymphomas, and sarcomas, it and could possibly lead to the discovery of ways to stop those events.

Developed by a team of researchers at the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; Bethesda, MD, USA), and the National Cancer Institute (NCI; Bethesda, MD, USA), both parts of the National Institutes of Health, and the Rockefeller University (New York, NY, USA), the technology centers on chromosomal rearrangements known as translocations. More...
Translocations occur when a broken strand of DNA from one chromosome is erroneously joined with that of another chromosome. Sometimes these irregularities can be beneficial in that they enable the immune system to respond to a vast number of microorganisms and viruses. However, translocations can also result in tumors.

The study’s findings were reported in the September 30, 2011, issue of the journal Cell. Translocations can take place during the course of normal cell division, when each chromosome--a single strand of DNA containing many genes--is copied verbatim to provide genetic information for the daughter cells. Occasionally, during this process, byproducts of normal metabolism or other factors can cause breaks in the DNA.

“The cell expresses specific enzymes whose primary purpose is to repair such lesions effectively, but when the enzymes mistakenly join pieces of two different chromosomes, the cell’s genetic information is changed,” said Rafael C. Casellas, PhD, senior investigator in the Genomics and Immunity Section at the NIAMS, who led the research team along with Michel C. Nussenzweig, MD, PhD, from Rockefeller University.

Scientists have known since the 1960s that recurrent translocations play a key role in cancer. What was not clear was how these genetic abnormalities are created, since very few of them were examined, and only within the context of tumors, according to Dr. Casellas. To better understand the nature of these tumor-inducing rearrangements, the authors had to create a system to visualize their appearance in normal, nontransformed cells.

The system the scientists designed involved introducing enzymes that recognize and cause damage at a particular sequence in the DNA into cells from mice, thereby constructing a genome where a unique site is broken continuously. The investigators then utilized a method called polymerase chain reaction (PCR)--which allows scientists to rapidly quickly amplify short sequences of DNA--to inspect all the sites in the genome that would get translocated to this particular break. Using this technique, they were able to explore more than 180,000 chromosomal rearrangements from 400 million white blood cells, called B cells.

Based on this large data set, the scientists were able to make several significant observations about the translocation process. They determined that most of the translocations involve gene domains, instead of the space on the DNA between the genes. They also discovered that most translocations target active genes, with a clear predisposition for the beginning of the gene, as opposed to its middle or end. The team also showed that a specific enzyme that normally creates DNA breaks in B cells dramatically increases the incidence of translocations during the immune response. This characteristic clarifies the long-standing observation that more than 95% of human lymphomas and leukemias are of B cell origin.

“This knowledge is allowing us to understand how tumors are initiated,” concluded Dr. Casellas. “It is the kind of information that in the near future, might help us prevent the development of cancer.”

Related Links:

National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Cancer Institute
National Institutes of Health, and the Rockefeller University




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.